[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575041":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":62,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":32,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":32,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":32,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Alzheimer's Disease Patients - Treatment","ACTIVE_COMPARATOR","Patients within the Alzheimer's continuum will be selected based on the National Institute of Aging - Alzheimer's Association Diagnostic Framework and be either classified as having mild cognitive impairment or mild-to-moderate dementia. Participants will undergo two PET\u002FMR sessions in which CMRGlu and CMRO2 will be imaged simultaneously by PET and qBOLD MRI. For validation, CMRO2 will also be imaged by PMROx prior to FDG injection. The study will follow a crossover design in which participants will receive ketogenic supplement prior to imaging.",[13],"Dietary Supplement: Ketogenic Supplement",{"label":15,"type":16,"description":17,"interventionNames":18},"Alzheimer's Disease Patients - Placebo","PLACEBO_COMPARATOR","Patients within the Alzheimer's continuum will be selected based on the National Institute of Aging - Alzheimer's Association Diagnostic Framework and be either classified as having mild cognitive impairment or mild-to-moderate dementia. Participants will undergo two PET\u002FMR sessions in which CMRGlu and CMRO2 will be imaged simultaneously by PET and qBOLD MRI. For validation, CMRO2 will also be imaged by PMROx prior to FDG injection. The study will follow a crossover design in which participants will receive a placebo drink prior to imaging.",[19],"Other: Placebo Drink",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Ketogenic Supplement","Commercially available ketone ester drink",[9],[27],"Ketone-IQTM",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo Drink","Placebo drink containing sunflower oil.",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Keith St Lawrence, PhD","Lawson Research Institute","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","(519) 646-6100","65737","kstlawr@uwo.ca",[45],{"facility":36,"status":32,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"London","Ontario","N6A 4BQ","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-81.23304,42.98339,{"lat":55,"lon":54},[58,59],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":35,"role":37,"phone":32,"phoneExt":32,"email":32},{"type":61,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[63,66],{"name":64,"class":65},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"name":67,"class":6},"University of Western Ontario, Canada","100575041","supplementing-neuro-energy-to-aid-cognition-100575041",false,"NCT06767124","Supplementing Neuro-Energy to Aid Cognition","Simultaneous PET\u002FMR Imaging of Brain Glucose and Oxygen Metabolism to Assess Energy Deficits Related to Alzheimer's Disease and the Response to Intervention","Inclusion Criteria - Healthy Participants: Males and females, Age 21 - 80 years, BMI of 18.5-30\n\nInclusion Criteria - Alzheimer's Disease Participants: Positive amyloid and tau biomarkers (as noted by PET imaging, cerebrospinal fluid or blood), Mild cognitive impairment or mild-to-moderate dementia, BMI of 18.5-30\n\nExclusion Criteria: Contraindications to MRI (claustrophobia, metal implants, pacemakers, etc.), Pregnant or breastfeeding women, Neurological disease (healthy participants only), Mental illness, Overt cardio- or neurovascular disease, Recent participation in any procedure(s) involving radioactive agents",true,"ALL","21 Years",{"count":79,"type":80},17,"ESTIMATED","INTERVENTIONAL",[83],"NA","It is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging.",[86],"Alzheimer Disease and Related Dementias (ADRD)",[88],"PET\u002FMR, Keytone Supplement, Brain Energy Metabolism","NOT_YET_RECRUITING","2026-07-27",{"date":92,"type":93},"2026-07-28","ACTUAL",{"date":95,"type":80},"2026-09-01",{"date":97,"type":80},"2028-05",{"name":5,"class":6},1]